Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL22345157 | 0.76 | ALDH1A1 (0.54) | ALDH1A1FKBP5MAPTLMNAKMT2A | |
| SCHEMBL317892 | 0.76 | MAPT (0.40) | ALDH1A1MAPTLMNAKMT2ACCR6 | |
| Naphthalene SCHEMBL338629 | 0.74 | ALDH1A1 (0.65) | ALDH1A1FKBP5MAPK10 | |
| Naphthalene SCHEMBL2123892 | 0.74 | ALDH1A1 (0.65) | ALDH1A1FKBP5MAPK10 | |
| SCHEMBL21359837 | 0.73 | MAPT (0.38) | ALDH1A1MAPTLMNAKMT2ACCR6 | |
| Hydrochloric Acid SCHEMBL2948518 | 0.73 | MAPT (0.38) | ALDH1A1MAPTLMNAKMT2ACCR6 | |
| Naphthoquinone SCHEMBL20603053 | 0.73 | CDC25B (0.54) | ALDH1A1FKBP5MAPTLMNAKMT2A | |
| Phthalic Anhydride SCHEMBL15568926 | 0.73 | TDP1 (0.54) | ALDH1A1FKBP5MAPTKMT2AMAOA | |
| Naphthoquinone SCHEMBL29667860 | 0.73 | CDC25B (0.54) | ALDH1A1FKBP5MAPTLMNAKMT2A | |
| Phthalimide SCHEMBL15948306 | 0.73 | GSK3B (0.58) | ALDH1A1FKBP5MAPTLMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | ALDH1A1 3961/4885FKBP5 3591/4885MAPT 619/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | ALDH1A1 2518/4885FKBP5 4610/4885MAPT 2756/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | ALDH1A1 4022/4885FKBP5 3781/4885MAPT 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.